Urgent care study of the LumiraDx SARS-CoV-2 Ag Test for rapid diagnosis of COVID-19

Diagnostic and Prognostic Research

Jared Gresh¹  Harold Kisner²  Brian DuChateau³ 

[1] Compass Medical, East Bridgewater, MA, USA;LumiraDx, Waltham, MA, USA;Compass Medical, East Bridgewater, MA, USA;NECAPS INC, Charlestown, RI, USA;LumiraDx, Waltham, MA, USA;

关键词: Antigen testing;    Community-based setting;    COVID-19;    False negative;    SARS-CoV-2;    Rapid diagnosis;   

DOI  :  10.1186/s41512-021-00113-7

来源: Springer

【 摘 要 】

BackgroundTesting individuals suspected of severe acute respiratory syndrome–like coronavirus 2 (SARS-CoV-2) infection is essential to reduce the spread of disease. The purpose of this retrospective study was to determine the false negativity rate of the LumiraDx SARS-CoV-2 Ag Test when utilized for testing individuals suspected of SARS-CoV-2 infection.MethodsConcurrent swab samples were collected from patients suspected of SARS-CoV-2 infection by their healthcare provider within two different urgent care centers located in Easton, MA, USA and East Bridgewater, MA, USA. One swab was tested using the LumiraDx SARS-CoV-2 Ag Test. Negative results in patients considered at moderate to high risk of SARS-CoV-2 infection were confirmed at a regional reference laboratory by polymerase chain reaction (PCR) using the additional swab sample. The data included in this study was collected retrospectively as an analysis of routine clinical practice.ResultsFrom October 19, 2020 to January 3, 2021, a total of 2241 tests were performed using the LumiraDx SARS-CoV-2 Ag Test, with 549 (24.5%) testing positive and 1692 (75.5%) testing negative. A subset (800) of the samples rendering a negative LumiraDx SARS-CoV-2 Ag Test was also tested using a PCR-based test for SARS-CoV-2. Of this subset, 770 (96.3%) tested negative, and 30 (3.8%) tested positive. Negative results obtained with the LumiraDx SARS-CoV-2 Ag test demonstrated 96.3% agreement with PCR-based tests (CI 95%, 94.7–97.4%). A cycle threshold (CT) was available for 17 of the 30 specimens that yielded discordant results, with an average CT value of 31.2, an SD of 3.0, and a range of 25.2–36.3. CT was > 30.0 in 11/17 specimens (64.7%).ConclusionsThis study demonstrates that the LumiraDx SARS-CoV-2 Ag Test had a low false-negative rate of 3.8% when used in a community-based setting.

【 授权许可】

CC BY